-transparent.png){kind=logo}
Oxaliplatin is a new platinum derivative. A multicentric phase I study was conducted with a monotherapy of Oxaliplatin. A total of 20 patients were enrolled who had histologically proven 6 ovarian cancers, 5 uterine cervix cancers, 3 lung cancers, 3 breast cancers, 1 endometrial cancer, 1 gastric cancer, and 1 colorectal cancer. Oxaliplatin was administered as a 2-hour infusion at doses of 20, 40, 80, 130, and 180 mg/m2 every 3 weeks, for a total of 30 cycles. A dose-related and reversible peripheral sensory neuropathy was the dose-limiting toxicity with minimal hematotoxicity and no nephrotoxicity. No hydration was needed. The plasma platinum concentration was biphasically decreased. Cmax and AUC were dose-dependent. T1/2 beta was 31.3 hours. The recommended dose for further studies was 130 mg/m2. A partial response was observed in endometrial cancer.
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
February 2009,
Cancer chemotherapy and pharmacology,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
January 1990,
Cancer chemotherapy and pharmacology,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
December 2013,
Investigational new drugs,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
February 2006,
American journal of clinical oncology,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
March 2007,
Cancer chemotherapy and pharmacology,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
March 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
January 2006,
Anticancer research,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
April 2006,
Anti-cancer drugs,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
January 2004,
Anticancer research,
T Taguchi, and
S Tsukagoshi, and
H Furue, and
H Niitani, and
K Noda
August 2014,
Investigational new drugs,
